Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting response to BET inhibitors using computational modeling: A BEAT AML project study

8 Jan 2019

Abstract excerpt

Despite advances in understanding the molecular pathogenesis of acute myeloid leukaemia (AML), overall survival rates remain low. The ability to predict treatment response based on individual cancer genomics using computational modeling will aid in the development of novel therapeutics and personalize care. Here, we used a combination of genomics, computational biology modeling (CBM), ex vivo chemosensitivity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30642575
DOI: 10.1016/j.leukres.2018.11.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting response to BET inhibitors using computational modeling: A BEAT AML project studyPMID 30642575Read ↗

Combining clinical and molecular data for personalized treatment in acute myeloid leukemia: A machine learning approach.Semantic proximity Read ↗

Machine Learning for Predicting Therapeutic Outcomes in Acute Myeloid Leukemia PatientsSemantic proximity Read ↗

Utilizing proteomics and phosphoproteomics to predict <i>ex vivo</i> drug sensitivity across genetically diverse AML patientsSemantic proximity Read ↗

Calibrated Uncertainty Quantification for Patient-Level AML Drug Sensitivity Prediction Using Split Conformal PredictionSemantic proximity Read ↗

Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.Semantic proximity Read ↗

Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity predictionSemantic proximity Read ↗

Clinical Forecasting using <i>Ex Vivo</i> Drug Sensitivity Profiling of Acute Myeloid LeukemiaSemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling.Semantic proximity Read ↗

Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature.Semantic proximity Read ↗

Proteomics and Phosphoprotoemic Measurements Enhance Ability to Predict Ex Vivo Drug Response in AMLSemantic proximity Read ↗

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.